论文部分内容阅读
为评价硫酸奈替米星的临床疗效及安全性，在１７０例急性细菌感染性病人中作多中心临床研究。结果显示：硫酸奈替米星的有效率（９５．３％）显著高于对照药硫酸丁胺卡那的有效率（８４．１％），试验组病人咳痰和腰痛症状的平均下降显著高于对照组；硫酸奈替米星治疗后细菌清除率达９７．２％；２组病人不良反应发生率均为４．８％，对照组中有２例（３．２％）出现耳鸣、１例（１．６％）听力减退，但试验组病人用药后未发现听力异常。结论：硫酸奈替米星临床疗效优于硫酸丁胺卡那且较少耳毒性。
To evaluate the clinical efficacy and safety of netilmycin sulfate, a multicenter clinical study of 170 acute bacterial infections was performed. The results showed that the effective rate of netilmicin sulfate (95.3%) was significantly higher than that of the reference drug amine amikacin (84.1%), and the mean drop of sputum and low back pain symptoms was significantly higher in the experimental group In the control group, the bacterial clearance rate was 97.2% after netilmicin sulfate treatment. The incidence of adverse reactions in both groups was 4.8%, while in the control group, tinnitus was found in 2 cases (3.2%), 1 Cases (1.6%) hearing loss, but the test group patients did not find any abnormal hearing after treatment. Conclusion: The clinical efficacy of netilmicin sulfate is better than that of amikacin and less ototoxicity.